New data from the TakeAim Leukemia trial of emavusertib, including data presented at the 64th American Society of Hematology Annual Meeting, will be discussed in a webcast hosted by Curis, Inc. (NASDAQ: CRIS) on Monday, December 12, 2022, at 10:00 a.m. ET.

Twenty-eight additional evaluable AML/MDS patients will be presented in this talk.

11 patients from certain populations who received monotherapy (now 24 patients total)
13 patients from outside the intended population who received monotherapy (now 34 patients total)
Four patients who had both emavusertib and venetoclax (4 patients total)
Patients that have specific mutations in genes like FLT3, U2AF1, or SF3B1 are considered part of a defined subset of the patient population.

Robert Martell, M.D., Head of Curis R&D, and Eric Winer, M.D., Clinical Investigator at the Dana-Farber Cancer Institute, will present during the call led by James Dentzer, President and CEO. At the end of the session, the speakers and other members of Curis’ leadership team will be present to answer any remaining questions.

Source: Prnewswire